The FDA has issued a warning letter to Novo Nordisk for violating postmarketing adverse drug experience regulations that include failure to report adverse events among patients taking GLP-1s. Chronic ...

Healthline News reports on emerging research, new treatments, diet, exercise, and trending topics in health and wellness. All articles are written by our network of editors and contributors.